Death of Research Subject Prompts Debate About Oversight of Gene-Therapy Trials

Scientists, bioethicists, and industry representatives last week debated measures to intensify government oversight of gene-therapy experiments following the death of a teenager enrolled in a clinical trial at the University of Pennsylvania.

The safety of the experiments has come under close scrutiny since 18-year-old Jesse Gelsinger died in September, the first fatality attributed directly to gene therapy. The technique aims to give patients new genes to treat diseases and inherited

Digital or Print Subscription

Already have an account? Log In Now.